Complement interactions with amyloid β1–42: A nidus for inflammation in AD brains

Complement activation and its deposition on β-amyloid plaques in Alzheimer's Disease (AD) brains correlates with the development of AD dementia. Results from immunocytochemical studies suggest that the appearance of complement activation in AD brains results in part from a direct interaction with the β-amyloid (Aβ) peptide Aβ–42, the major peptide of β-amyloid plaques. To study this possibility, we exposed aggregated Aβ of different lengths to complement present in normal human serum (NHS) in vitro. NHS contains two pathways for complement activation, the classical and alternative. Solubilization of bound complement proteins and immunoblotting reveal that aggregated Aβ1–42 binds larger amounts of complement proteins C1q, C4, C3, C5 and C6, than aggregated Aβ1–40, Aβ1–28 and Aβ 17–43. The binding of C3, unlike CIq and C4, requires complement activation. In NHS, C3 binding to aggregated Aβ1–42 occurs by both the alternative path-way and, to a lesser extent, the classical pathway. The activation of C3 by bot...

[1]  M. Emmerling,et al.  Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide. , 1997, Immunopharmacology.

[2]  H. Wiśniewski,et al.  The “Nonamyloidogenic” p3 Fragment (Amyloid β17-42) Is a Major Constituent of Down's Syndrome Cerebellar Preamyloid* , 1996, The Journal of Biological Chemistry.

[3]  Marla Gearing,et al.  Aβ 40 is a major form of β-amyloid in nonhuman primates , 1996, Neurobiology of Aging.

[4]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[5]  L. Lue,et al.  Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. , 1996, Journal of neuropathology and experimental neurology.

[6]  A. Roher,et al.  Specific Domains of β-Amyloid from Alzheimer Plaque Elicit Neuron Killing in Human Microglia , 1996, The Journal of Neuroscience.

[7]  Douglas Walker,et al.  Inflammation and Alzheimer's disease pathogenesis , 1996, Neurobiology of Aging.

[8]  R. Veerhuis,et al.  The role of complement and activated microglia in the pathogenesis of Alzheimer's disease , 1996, Neurobiology of Aging.

[9]  Brian J Cummings,et al.  Localization and Cell Association of C1q in Alzheimer's Disease Brain , 1996, Experimental Neurology.

[10]  T. Iwatsubo,et al.  Association of A beta 40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[11]  P. Gasque,et al.  Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. , 1995, Journal of immunology.

[12]  D. Mann,et al.  Microglial cells and amyloid ? protein (A?) deposition: association with A?40-containing plaques , 1995 .

[13]  S. Whittemore,et al.  Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia , 1995, Journal of Neuroimmunology.

[14]  P. Gasque,et al.  Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. , 1995, Journal of immunology.

[15]  D. Walker,et al.  Complement and cytokine gene expression in cultured microglia derived from postmortem human brains , 1995, Journal of neuroscience research.

[16]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[17]  C. Glabe,et al.  Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation. , 1994, The Journal of biological chemistry.

[18]  David A. Willoughby,et al.  Selective expression of clusterin (SGP-2) and complement C1qB and C4 during responses to neurotoxinsin vivo andin vitro , 1994, Neuroscience.

[19]  L. Thal,et al.  Lack of long-term effects after β-amyloid protein injections in rat brain , 1994, Neurobiology of Aging.

[20]  C. Cotman,et al.  beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. , 1994, Journal of immunology.

[21]  M. Ball,et al.  Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. , 1994, The Journal of biological chemistry.

[22]  M J Ball,et al.  beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  L. Lue,et al.  Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease. , 1993, Brain research. Molecular brain research.

[24]  P. Mcgeer,et al.  Complement activation by beta-amyloid in Alzheimer disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Selkoe,et al.  Synthetic amyloid β-protein fails to produce specific neurotoxicity in monkey cerebral cortex , 1992, Neurobiology of Aging.

[26]  I. Lieberburg,et al.  Lack of alzheimer pathology after β-amyloid protein injections in rat brain , 1992, Neurobiology of Aging.

[27]  G. Cole,et al.  Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. , 1992, The American journal of pathology.

[28]  H. Fraser,et al.  Cerebral amyloid plaques in Alzheimer’s disease but not in scrapie-affected mice are closely associated with a local inflammatory process , 1991, Virchows Archiv. B, Cell pathology including molecular pathology.

[29]  G. Cole,et al.  Effects of injected Alzheimer beta-amyloid cores in rat brain. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. Cotman,et al.  Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. , 1991, European journal of pharmacology.

[31]  P. Mcgeer,et al.  Reactions of the Immune System in Chronic Degenerative Neurological Diseases , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[32]  D. Selkoe,et al.  Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease. , 1991, The American journal of pathology.

[33]  P. Eikelenboom,et al.  Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease , 1990, Neuroscience Letters.

[34]  B. Morgan Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. , 1989, The Biochemical journal.

[35]  A. Campbell,et al.  IMMUNOCYTOCHEMICAL LOCALIZATION OF THE TERMINAL COMPLEMENT COMPLEX IN MULTIPLE SCLEROSIS , 1989, Neuropathology and applied neurobiology.

[36]  T. Sato,et al.  Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. , 1984, Japanese journal of pharmacology.

[37]  R. Levine,et al.  Binding reaction between the third human complement protein and small molecules. , 1981, Biochemistry.

[38]  M. Pangburn,et al.  Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. , 1981, Biochemistry.

[39]  R. Levine,et al.  Covalent binding and hemolytic activity of complement proteins. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Thomas,et al.  Evidence for presence of an internal thiolester bond in third component of human complement. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Levine,et al.  Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces. , 1979, Journal of immunology.

[42]  T. Poulos,et al.  Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis , 1997, Nature Medicine.

[43]  H. Levine Thioflavine T interaction with amyloid β-sheet structures , 1995 .

[44]  S. Barnum Complement biosynthesis in the central nervous system. , 1995, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[45]  D. Selkoe,et al.  Microinjection of synthetic amyloid beta-protein in monkey cerebral cortex fails to produce acute neurotoxicity. , 1993, The American journal of pathology.

[46]  E. Pryzdial,et al.  A reexamination of the role of magnesium in the human alternative pathway of complement. , 1986, Molecular immunology.